The DOI matches its Crossref record; 233 of the 233 references it cites were found in a registry or an index.
Cisplatin: The first metal based anticancer drug
Abstract
Cisplatin or (SP-4-2)-diamminedichloridoplatinum(II) is one of the most potential and widely used drugs for the treatment of various solid cancers such as testicular, ovarian, head and neck, bladder, lung, cervical cancer, melanoma, lymphomas and several others. Cisplatin exerts anticancer activity via multiple mechanisms but its most acceptable mechanism involves generation of DNA lesions by interacting with purine bases on DNA followed by activation of several signal transduction pathways which finally lead to apoptosis. However, side effects and drug resistance are the two inherent challenges of cisplatin which limit its application and effectiveness. Reduction of drug accumulation inside cancer cells, inactivation of drug by reacting with glutathione and metallothioneins and faster repairing of DNA lesions are responsible for cisplatin resistance. To minimize cisplatin side effects and resistance, combination therapies are used and have proven more effective to defect cancers. This article highlights a systematic description on cisplatin which includes a brief history, synthesis, action mechanism, resistance, uses, side effects and modulation of side effects. It also briefly describes development of platinum drugs from very small cisplatin complex to very large next generation nanocarriers conjugated platinum complexes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–233 of 233
Beyond Photodynamic Therapy: Light-Activated Cancer Chemotherapy
Reeßing, F., & Szymański, W. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160906103223 · Cited by 69
DNA Damage Recognition and Nucleotide Excision Repair in Mammalian CellsPreprint
Wood, R. D., Araújo, S. J., Ariza, R. R., Batty, D. P., Biggerstaff, M., Evans, E. L., Gaillard, P.-H. L., Gunz, D., Köberle, B., Kuraoka, I., et al. (2000) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2000.65.173 · Cited by 65
Near infrared activation of an anticancer Pt IV complex by Tm-doped upconversion nanoparticles
Ruggiero, E., Hernández‐Gil, J., Rivas, J. C. M., & Salassa, L. (2014) · Chemical Communications · doi:10.1039/c4cc07960d · Cited by 65
Principles of cytotoxic chemotherapy
Lind, M. (2008) · Medicine · doi:10.1016/j.mpmed.2007.10.003 · Cited by 65
Prevention of cisplatin nephrotoxicity
Broe, M. E. D., & Wedeen, R. P. (1986) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(86)90001-5 · Cited by 64
Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer
Koster, R., van Vugt, M. A. T. M., Timmer‐Bosscha, H., Gietema, J. A., & de Jong, S. (2013) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2013.13 · Cited by 64
Prevention of cisplatin nephrotoxicity.
Hayati, F., Hossainzadeh, M., Shayanpour, S., Abedi-Gheshlaghi, Z., & Mousavi, S. S. B. (2016) · PubMed Central · Cited by 62
Principles of cytotoxic chemotherapy
Lind, M. (2011) · Medicine · doi:10.1016/j.mpmed.2011.09.009 · Cited by 60
Status of Bi- and Multi-Nuclear Platinum Anticancer Drug Development
Zhang, J., Wang, L., Xing, Z.-Y., Liu, D., Sun, J., Li, X., & Zhang, Y. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010791162270 · Cited by 58
Awuah, S. G., Riddell, I. A., & Lippard, S. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615327114 · Cited by 53
Coordination-driven self-assembly of a Pt( iv ) prodrug-conjugated supramolecular hexagon
Yue, Z., Wang, H., Li, Y., Qin, Y., Xu, L. S., Bowers, D. J., Gangoda, M. E., Li, X., Yang, H., & Zheng, Y. (2017) · Chemical Communications · doi:10.1039/c7cc07622c · Cited by 51
The efficacy of surgical treatment of cancer – 20years later
Benjamin, D. J. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.01.004 · Cited by 48
8. COORDINATION COMPLEXES OF TITANIUM(IV) FOR ANTICANCER THERAPY
Tshuva, E. Y., & Miller, M. (2018) · De Gruyter eBooks · doi:10.1515/9783110470734-008 · Cited by 47
Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines
Skowron, M. A., Melnikova, M., van Roermund, J. G. H., Romano, A., Albers, P., Thomale, J., Schulz, W. A., Niegisch, G., & Hoffmann, M. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020590 · Cited by 44
Günes, D. A., Florea, A.-M., Splettstoesser, F., & Büsselberg, D. (2008) · NeuroToxicology · doi:10.1016/j.neuro.2008.12.001 · Cited by 42
Biological activity of PtIV prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis
Castro, S. A., Terenzi, A., Hager, S., Englinger, B., Faraone, A., Calvo, J., Galanski, M. S., Keppler, B. K., Berger, W., & Salassa, L. (2018) · Scientific Reports · doi:10.1038/s41598-018-35655-2 · Cited by 41
Cisplatin-induced apoptosis in human promyelocytic leukemia cells
Previati, M., Lanzoni, I., Corbacella, E., Magosso, S., Guaran, V., Martini, A., & Capitani, S. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.18.3.511 · Cited by 40
Alizadehnohi, M., Nabiuni, M., Nazari, Z., Safaeinejad, Z., & Irian, S. (2012) · PubMed · Cited by 39
Kindlin-2 controls sensitivity of prostate cancer cells to cisplatin-induced cell death
Gong, X., An, Z., Wang, Y., Guan, L., Fang, W., Strömblad, S., Jiang, Y., & Zhang, H. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.08.003 · Cited by 39
Future trends and emerging issues for nanodelivery systems in oral and oropharyngeal cancer
Irimie, A. I., Sonea, L., Jurj, A. M., Mehterov, N. H., Zimța, A., Budişan, L., Braicu, C., & Berindan‐Neagoe, I. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s133219 · Cited by 39
Strategies to prevent nephrotoxicity of anticancer drugs
Skinner, R. (1995) · Current Opinion in Oncology · doi:10.1097/00001622-199507000-00003 · Cited by 34
Two 4N Cell-Cycle Arrests Contribute to Cisplatin-Resistance
Shen, H., Perez, R. E., Davaadelger, B., & Maki, C. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059848 · Cited by 34
Apostolou, P., Toloudi, M., Chatziioannou, M., Ioannou, E., Knocke, D. R., Nester, J., Komiotis, D., & Papasotiriou, I. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-18 · Cited by 33
Platinum resistance: Laboratory findings and clinical implications
Muggia, F. M., & Los, G. (1993) · Stem Cells · doi:10.1002/stem.5530110304 · Cited by 32
Ichinose, Y., Yosimori, K., Yoneda, S., Kuba, M., Kudoh, S., Niitani, H., & for the Japan UFT Lung Cancer Study Group (2000) · Cancer · Cited by 29
Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer
Pinto‐Leite, R., Arantes‐Rodrigues, R., Palmeira, C., Colaço, B., Lopes, C., Colaço, A. A., Costa, C., Silva, V. M., Oliveira, P. A., & Santos, L. L. (2012) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2012.11.007 · Cited by 28
BIOCHEMICAL AND MOLECULAR MECHANISMS OF ACTION OF CISPLATIN IN CANCER CELLS
Petrović, M., & Todorović, D. (2016) · Cited by 28
Combined anticancer activity of osthole and cisplatin in NCI-H460 lung cancer cells in vitro
Xu, X., Zhang, Y., Qu, D. C., Liu, H., Gu, X., Jiao, G., & Zhao, L. (2013) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2013.889 · Cited by 25
Iwasaki, Y., Nagata, K., Nakanishi, M., Natuhara, A., Kubota, Y., Ueda, M., 有本, 太., & Hara, H. (2005) · CHEST Journal · doi:10.1378/chest.128.4.2268 · Cited by 24
Synthesis of Ptsome: a platinum-based liposome-like nanostructure
Aryal, S., Hu, C. J., & Zhang, L. (2012) · Chemical Communications · doi:10.1039/c2cc18176b · Cited by 23
Hemati, S., Jolfaie, N. A., Gookizadeh, A., & Rafienia, M. (2012) · Journal of Research in Medical Sciences · Cited by 21
Štarha, P., Smola, D., Tuček, J., & Trávnı́ček, Z. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16012034 · Cited by 19
Tetraarsenic oxide and cisplatin induce apoptotic synergism in cervical cancer
Byun, J. M., Jeong, D. H., Lee, D. S., Kim, J. R., Park, S. G., Kang, M. S., Kim, Y. N., Lee, K. B., Sung, M. S., & Kim, K. T. (2013) · Oncology Reports · doi:10.3892/or.2013.2243 · Cited by 16
Cited by
Zafar, A., Khatoon, S., Khan, M. J., Abu, J., & Naeem, A. (2025) · Discover Oncology · doi:10.1007/s12672-025-02198-8 · Cited by 565
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
Chen, S.-H., & Chang, J.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174136 · Cited by 428
Overcoming cancer chemotherapy resistance by the induction of ferroptosis
Wang, Y., Wu, X., Ren, Z., Li, Y., Zou, W., Chen, J., & Wang, H. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100916 · Cited by 361
Metadata
- Authors
- Ghosh, S.
- Venue
- Bioorganic Chemistry
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 88
- Pages
- 102925
- ISSN
- 0045-2068 (ISSN-L)
- OpenAlex
- W2937766145
- Cited by
- 1,751
- References
- 233
- FWCI
- 56.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.